Castle Biosciences (CSTL) CCO Juvenal Tobin Sells 9,050 Shares

What Happened

• Juvenal Tobin W, Chief Commercial Officer of Castle Biosciences (CSTL), sold 9,050 shares in an open-market transaction on August 25, 2026. The weighted-average sale price was $35.04, for total proceeds of about $317,112. This was a sale (routine disposition) rather than a purchase.

Key Details

• Transaction date: August 25, 2026
• Trade type/code: Sale (S) — open-market disposition
• Shares sold: 9,050; weighted-average price: $35.04; total proceeds ≈ $317,112
• Price range / execution: trades executed at prices from $35.00 to $35.14; reported price is the weighted average (reporting person can provide full per-trade details on request, per footnote)
• Plan: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted December 10, 2025
• Filing timeliness: Report filed August 27, 2026 for an August 25 transaction — appears timely under Form 4 reporting rules
• Shares owned after transaction: not specified in the provided filing summary

Context

• A sale under a Rule 10b5-1 plan means the trades were executed according to a pre-established plan, which is commonly used to avoid timing-based accusations; it does not by itself indicate insider sentiment about the company.
• For retail investors, purchases generally carry more interpretive weight than routine sales; this filing documents a routine, pre-planned sale by a senior executive.